Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.